Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159726 | 1.00 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL7962292 | 0.82 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL18162806 | 0.82 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL13609239 | 0.82 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL28093400 | 0.81 | CYP3A4 (0.93) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL12234246 | 0.81 | CYP3A4 (0.61) | CYP3A4SLC7A5 | |
| SCHEMBL12234260 | 0.81 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL2761646 | 0.81 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5497653 | 0.80 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL19974306 | 0.80 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | CYP3A4 160/4885SLC7A5 2134/4885HRH4 800/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | CYP3A4 160/4885SLC7A5 2134/4885HRH4 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.